Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

OPKO Health Inc 's longer-acting clotting factor VIIa-CTP receives orphan drug designation in the U.S.


Friday, 28 Feb 2014 09:58am EST 

OPKO Health Inc:Announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to OPKO's longer-acting version of clotting Factor VIIa (Factor VIIa-CTP) for the treatment of bleeding episodes in patients with hemophilia A or B with inhibitors to Factor VIII or Factor IX.These patients are currently being treated by commercially-available Factor VIIa, with estimated 2013 worldwide sales of $1.7 billion. 

Company Quote

9.6
0.14 +1.48%
19 Dec 2014